Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icapamespib - Samus Therapeutics

Next Previous
X
Search
Drug Profile

Icapamespib - Samus Therapeutics

Alternative Names: PU-AD; PU-HZ151

Latest Information Update: 28 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samus Therapeutics
  • Developer Memorial Sloan-Kettering Cancer Center; Samus Therapeutics
  • Class Amines; Antidementias; Antineoplastics; Benzodioxoles; Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Amyotrophic lateral sclerosis
  • No development reported Brain injuries; Glioblastoma

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent, Second-line therapy or greater) in USA (PO)
  • 18 Apr 2023 Samus Therapeutics terminates a phase I trial in Alzheimer's Disease (In volunteers) in the USA due to company ceased operations (NCT03935568)
  • 17 Nov 2022 Samus Therapeutics terminates phase IIa trial in Alzheimer's Disease in the US (NCT04311515)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top